These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18243335)

  • 1. Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
    Crespo-Facorro B; Carrasco-Marín E; Pérez-Iglesias R; Pelayo-Terán JM; Fernandez-Prieto L; Leyva-Cobián F; Vázquez-Barquero JL
    Psychiatry Res; 2008 Mar; 158(2):206-16. PubMed ID: 18243335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
    J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ramirez-Bonilla M; Martínez-Garcia O; Pardo-Garcia G; Caseiro O; Pelayo-Terán JM; Vázquez-Barquero JL
    J Psychopharmacol; 2011 Jun; 25(6):744-54. PubMed ID: 21292922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
    Lataster J; van Os J; de Haan L; Thewissen V; Bak M; Lataster T; Lardinois M; Delespaul PA; Myin-Germeys I
    J Clin Psychiatry; 2011 Oct; 72(10):1397-404. PubMed ID: 21208588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Caseiro O; Martínez-Garcia O; Pardo G; Ramirez-Bonilla M; Pelayo-Terán JM; Vázquez-Barquero JL
    J Psychiatr Res; 2011 Jun; 45(6):763-9. PubMed ID: 21106207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
    Crespo-Facorro B; Roiz-Santiáñez R; Pérez-Iglesias R; Pelayo-Terán JM; Rodríguez-Sánchez JM; Tordesillas-Gutiérrez D; Ramírez M; Martínez O; Gutiérrez A; de Lucas EM; Vázquez-Barquero JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1936-43. PubMed ID: 18930104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.
    Noto C; Ota VK; Gouvea ES; Rizzo LB; Spindola LM; Honda PH; Cordeiro Q; Belangero SI; Bressan RA; Gadelha A; Maes M; Brietzke E
    Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
    Pelayo-Terán JM; Diaz FJ; Pérez-Iglesias R; Suárez-Pinilla P; Tabarés-Seisdedos R; de León J; Crespo-Facorro B
    Psychol Med; 2014 Jan; 44(1):37-50. PubMed ID: 23461899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
    Sergi MJ; Green MF; Widmark C; Reist C; Erhart S; Braff DL; Kee KS; Marder SR; Mintz J
    Am J Psychiatry; 2007 Oct; 164(10):1585-92. PubMed ID: 17898351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
    Roiz-Santiáñez R; Tordesillas-Gutiérrez D; Ortíz-García de la Foz V; Ayesa-Arriola R; Gutiérrez A; Tabarés-Seisdedos R; Vázquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2012 Oct; 141(1):22-8. PubMed ID: 22884754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
    Pérez-Iglesias R; Mata I; Martínez-García O; Garcia-Unzueta MT; Amado JA; Valdizán EM; Vázquez-Barquero JL; Crespo-Facorro B
    J Clin Psychopharmacol; 2012 Dec; 32(6):804-8. PubMed ID: 23131886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
    Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
    J Clin Psychiatry; 2004 Jul; 65(7):940-7. PubMed ID: 15291683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
    Shim JC; Choe BM; Kim JG; Jae YM; Kim HC; Kim SG; Oh MK; Kelly DL; Conley RR
    J Clin Psychopharmacol; 2007 Aug; 27(4):400-1. PubMed ID: 17632229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.